Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Sells $43,223.84 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 902 shares of Mirum Pharmaceuticals stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $47.92, for a total value of $43,223.84. Following the completion of the transaction, the senior vice president now owns 3,524 shares of the company’s stock, valued at $168,870.08. The trade was a 20.38 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Jolanda Howe also recently made the following trade(s):

• On Tuesday, January 7th, Jolanda Howe sold 750 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $42.82, for a total transaction of $32,115.00.
• On Thursday, November 14th, Jolanda Howe sold 2,500 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $47.10, for a total transaction of $117,750.00.

Mirum Pharmaceuticals Price Performance

MIRM stock opened at $48.60 on Thursday. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33. The company has a market capitalization of $2.33 billion, a P/E ratio of -24.06 and a beta of 0.98. The business has a 50 day simple moving average of $44.03 and a 200-day simple moving average of $41.75. Mirum Pharmaceuticals, Inc. has a twelve month low of $23.14 and a twelve month high of $49.58.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The company had revenue of $90.38 million for the quarter, compared to the consensus estimate of $81.99 million. During the same period last year, the firm posted ($0.57) EPS. Mirum Pharmaceuticals’s revenue for the quarter was up 89.4% on a year-over-year basis. As a group, equities analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.45 EPS for the current year.

Institutional Trading of Mirum Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in MIRM. State Street Corp grew its stake in shares of Mirum Pharmaceuticals by 19.9% in the 3rd quarter. State Street Corp now owns 1,793,728 shares of the company’s stock valued at $69,955,000 after purchasing an additional 297,511 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Mirum Pharmaceuticals by 5.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 328,161 shares of the company’s stock worth $12,798,000 after purchasing an additional 17,149 shares during the period. Geode Capital Management LLC grew its position in Mirum Pharmaceuticals by 3.2% in the 3rd quarter. Geode Capital Management LLC now owns 936,197 shares of the company’s stock valued at $36,519,000 after buying an additional 29,017 shares during the last quarter. GSA Capital Partners LLP increased its stake in Mirum Pharmaceuticals by 791.7% in the 3rd quarter. GSA Capital Partners LLP now owns 57,985 shares of the company’s stock valued at $2,261,000 after buying an additional 51,482 shares during the period. Finally, Hennion & Walsh Asset Management Inc. raised its position in Mirum Pharmaceuticals by 25.5% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 145,599 shares of the company’s stock worth $6,021,000 after buying an additional 29,545 shares during the last quarter.

Wall Street Analyst Weigh In

MIRM has been the subject of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $66.00 price objective on shares of Mirum Pharmaceuticals in a research report on Wednesday, November 13th. Citigroup lifted their price target on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Leerink Partners increased their price objective on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. Finally, Robert W. Baird boosted their target price on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. Ten analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Mirum Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $57.10.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.